天茂集团:无法在法定期限内披露定期报告 股票停牌

Core Viewpoint - Tianmao Group announced that it is unable to disclose its annual report for 2024 within the statutory deadline due to the need for further verification and completion of certain information [1] Group 1: Company Announcement - The company has not completed the preparation of its 2024 annual report, leading to the inability to disclose it on time [1] - As a result, the company's stock will be suspended from trading starting May 6, 2025 [1] - If the company fails to disclose the 2024 annual report within two months of the stock suspension, it will face a delisting risk warning [1] Group 2: Delisting Risk - Should the delisting risk warning be implemented and the company still does not disclose more than half of the board's assurance of the report's authenticity, accuracy, and completeness within two months, the company's stock will be terminated from listing [1]

Biocause Pharma-天茂集团:无法在法定期限内披露定期报告 股票停牌 - Reportify